Author response for "Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison"
2020 ◽
2020 ◽
Efficacy and safety of
iGlarLixi
versus
IDegLira
in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison
2020 ◽
Vol 22
(11)
◽
pp. 2170-2178
◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽